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Abstract:  The free radical nitric oxide (NO
●) is known to play a dual role in human 
physiology and pathophysiology. At low levels, NO
● can protect cells; however, at higher 
levels, NO
● is a known cytotoxin, having been implicated in tumor angiogenesis and 
progression. While the majority of research devoted to understanding the role of NO
● in 
cancer has to date been tissue-specific, we herein review underlying commonalities of NO
● 
which may well exist among tumors arising from a variety of different sites. We also 
discuss the role of NO
● in human physiology and pathophysiology, including the very 
important relationship between NO
● and the glutathione-transferases, a class of protective 
enzymes involved in cellular protection. The emerging role of NO
● in three main areas of 
epigenetics—DNA methylation, microRNAs, and histone modifications—is then 
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discussed. Finally, we describe the recent development of a model cell line system in 
which human tumor cell lines were adapted to high NO
● (HNO) levels. We anticipate that 
these HNO cell lines will serve as a useful tool in the ongoing efforts to better understand 
the role of NO
● in cancer. 
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1. Background 
NO
● is a free radical which was discovered in 1980 as a ubiquitous diffusible second messenger. 
While some authors use the term “nitric oxide” to refer to any of the nitric oxide reactive species 
(NO
●, NO
-
, and NO
+), in biological settings, nitric oxide usually refers to the free radical. NO
● was 
determined to be a prominent constituent of what was then called endothelium-derived relaxing factor 
(EDRF) [1]. Later in 1985, Eschericia coli lipopolysacchride (LPS) was found to initiate production of 
NO
● by LPS-stimulated mouse macrophages [2]. We now know the molecule plays a significant role 
in both normal and abnormal physiology of human beings, as well as plants and invertebrates [3-5]. 
NO
● has a well characterized two-step synthetic metabolic pathway in which L-arginine is first 
converted to NG-hydroxy-L-arginine and then to L-citrulline and NO
●. This reaction is catalyzed by the 
enzymatic family of nitric oxide synthases (NOSs). Three NOS isoforms exist: 1) nNOS/NOS1, a 
calcium-dependent enzyme discovered in neurons that is involved in neural transmission; 2) 
iNOS/NOS2, a calcium-independent enzyme that releases large amounts of NO
● in response to 
macrophage activation with endotoxin and cytokines, and is involved in cytotoxicity; and 3) 
eNOS/NOS3, also a calcium-dependent enzyme that is constitutively expressed, isolated from 
endothelial cells, and is found in normal vascular endothelium [6,7]. Once NO
● is produced, it can 
react with various molecules, resulting in more stable compounds such as S-nitrosothiols, metal 
adducts, peroxynitrites (while in the presence of oxygen), and tetrahydrobiopterin (THB) [6]. THB is 
recognized as a necessary prerequisite for the biosynthesis of key aromatic amino acid hydroxylase 
enzyme precursors necessary for synthesis of neurotransmitters such as serotonin, melatonin, 
epinephrine and dopamine.  
It is believed NO
● regulates the physiology and pathophysiology of the body through one of three 
biomolecular mechanisms: 1) redox interactions with thiols, 2) coordinating interactions with metal 
functional centers, and 3) through protein kinase activity [8]. The role and impact of NO
● is believed 
to be widespread because of its ability to cross cell membranes in an unaltered chemical form, diffuse 
rapidly, interact with key generative and target cell-response proteins, and quickly interact with key 
transition metal containing proteins [6]. 
The various biomolecular mechanisms of NO
● result in numerous biological functions, including:  
1) antitumor and microbial immunity, including against gram positive organisms [6], 2) immuno-
modulation and allo-antigenicity [9,10], and 3) a signaling pathway [6]. Nearly every cell throughout 
the body has the ability to express calcium-independent iNOS [6]. Within the central nervous system, 
learning, sleep, feeding, male and female reproductive behavior are all impacted by NO
● [11]. It also 
influences the neurotransmitters in synapses between peripheral organs [11] and regulates Int. J. Mol. Sci. 2010, 11                 
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angiogenesis and neurogenesis after stroke activity [12]. NO
● also delays the aging of oocytes [13], 
controls resting potential in skeletal muscle [14], regulates contraction-excitation coupling [14], and 
modulates chondrocyte development during endochondral ossification [15]. Significantly, NO
● 
depravation is a critical underlying cause for endothelial dysfunction, which in turn is a key common 
contributor to diabetes-related cardiovascular disease, myocardial infarction, and atherosclerosis [16,17]. 
NO
● in low concentrations is now known to have benign, modulating, and regulatory effects on 
normal mammalian and human biology and physiology. Higher concentration levels of NO
● are now 
shown to be both damaging and pathologic to physiologic processes [6]. What is defined as a high or 
low level can vary enormously depending upon which physiologic system the free radical is found and 
the apparent contradictory functional impact of NO
● presence on a particular molecular mechanism 
and biochemical microenvironment [6]. For instance, at NO
● concentrations of less than 100 nM, 
cyclic guanosine monophosphate (cGMP), cGMP-dependent protein kinase (PKG) and extracellular 
signal regulated kinase (ERK) activation can occur. As concentration levels increase Akt is 
phosphorylated, and in ranges between 300 to 800 nM hypoxia inducible factor-1 alpha and p53 are 
stabilized [18]. As concentrations increase further, nitrosation and oxidative processes become 
prominent and initiate stressful cellular events [19]. However, the role of NO
● can be either protective 
or toxic, depending upon the unique biochemical content of the microenvironment in which it exists [20]. 
It is also now well established that NO
● plays a multifaceted and contradictory role in the biology 
and growth of tumors [21]. Over-expression of NOS has been shown to be responsible for tumor 
angiogenesis and maintaining vascular tone within tumor blood vessel systems [22-25], as well as the 
facilitation of neoplastic transformation [22,26,27]. Studies have shown that in cancer patients, NO
● 
regulates blood flow to tumors, and by down-regulating NO
● synthesis, a distinct vasoconstricting 
event results [22]. This has been demonstrated through the use of N-nitro-L-arginine (L-NNA) to 
reduce blood flow to tumors in BD9 rats with P22 carcinosarcoma [22,28]. In humans cancer patients 
reducing NOS results in an increase in blood pressure [22,29,30]. At higher concentrations in the 
proper microenvironment, for an extended period of time, NO
● exposure initiates inflammation, can 
stimulate tumor growth and/or metastatic behavior [6,7], and can lead to mutations and the clinical 
presentation of cancer [9,31,32]. Exogenous sources of NO
●, such as cigarette smoke, contribute to 
subcellular damage through the formation of N-nitrosoamines and N-nitrosamides, contributing to 
elevated expression of head and neck cancers [7,33-36].  
It is also well recognized that reactive oxygen species (ROSs) play an important function in either 
the protective or pathologic expression of NO
● reactions with oxygen [6,7]. ROSs provide beneficial 
impacts through killing of microorganisms and malignant cells, or a pathologic effect, again depending 
upon the microenvironment. Higher concentrations of ROS generate oxidative and nitrosative 
environmental stressors leading to: 1) DNA damage, 2) down-regulated antioxidants, and 3) an impact 
on transcription/translation activities, thereby generally impairing normal cellular function [7,37,38]. 
Should DNA become damaged from either endogenous or exogenous sources of NO
●, a number of 
defensive apoptotic systems are initiated to protect against unwanted cellular transformation [6,7]. 
Amongst the most important defensive apoptotic systems is the up regulation of DNA damage sensing 
proteins, such as p53. Damage not repaired typically results in cellular death through apoptosis. NO
● is 
also known to inhibit caspase activation, which in turn is known to induce normal apoptosis. Studies have 
also shown NO
● prohibits apoptosis in a variety of cell types, as well as in some tumor cells [39,40]. Int. J. Mol. Sci. 2010, 11                 
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2. GST-pi 
Thiols are a group of biological molecules which act as intracellular antioxidants. Among the most 
studied forms is glutathione (GSH), known to react with and neutralize electrophilic centers of a 
number of environmental and oxidative cellular stressors. The enzyme which catalyzes these reactions 
is glutathione S-transferase-pi (GST-pi), one of a family of Phase II detoxifying glutathione   
S-transferases (GSTs) responsible not only for detoxification, but also activation of significant 
biochemical pathways essential to normal physiology [41]. These oxidative stressors include elevated 
levels of NO
●. The GST isoenzymes and their behavior are essential to providing yet another tool 
toward protection of DNA from a variety of endogenous and exogenous pathogenic sources [42-44]. 
Equally important, the GSTs catalyze the conjugation of GSH to an array of xenobiotic or toxic 
compounds rendering them non-toxic [45]. Due to these behaviors GSTs are an important area of 
research in molecular biology. 
While GST isoenzymes relieve the source of toxicity, the catalytic group is also strongly implicated 
in the development of cellular resistance to anti-cancer drug therapy [42,45]. It provides a mechanism 
to explain cancer patients’ observed resistance to anticancer drug therapies [45]. Tumor cell lines 
which over-express GST-pi have heightened detoxification responses and acquire increased resistance 
to compounds perceived by the body as being toxic, including chemotherapeutic drugs [42,45,46]. 
GST isoenzymes are categorized into three primary groups: 1) cytosolic, 2) membrane-bound 
microsomal, and 3) mitochondrial [45]. The cytosolic type is further divided into seven classes: 1) 
Alpha, 2) Mu, 3) Omega, 4) Pi, 5) Sigma, 6) Theta, and 7) Zeta [45]. GST-pi is now recognized to be 
the predominant isoform subclass [42,44].  
The GST-pi gene has four functional polymorphisms (GSTP1*A, GSTP1*B, GSTP1*C, and 
GSTP1*D), with each allelic genotype having different treatment response outcomes among individual 
cancer patients [45,47]. Examples include: 1) GSTP1*A is responsible for acquired resistance to 
cisplatin treatment due to creation of platinum-GSH conjugates [48], 2) GSTP1*B, which in certain 
circumstances, is associated with an impaired ability to detoxify platinum based therapeutic treatment 
[49], and 3) patients testing positive for GSTP1*C appear to experience breast cancer with less 
frequency [50]. All polymorphisms have been shown to impact, to varying degrees: 1) anticancer 
therapy treatment, 2) chemotherapeutic response, and 3) susceptibility to cancer. Most importantly, 
GSTP1 has been reported to be over-expressed in a number of different tumor types including: colon, 
lymphoma, pancreas, breast, NSCLC and ovarian [42,51]. One effort analyzed GST enzymes, GST 
composition, and GSH concentration levels in normal and squamous cell carcinoma tissues among  
25 patients (14 with oropharyngeal or oral tumors, 11 with laryngeal tumors) [44]. GST-pi levels 
increased in 11 of the 14 oral cavity tumors, and elevated expression of GST-pi was found in all 
laryngeal tumors [44]. Another report provides evidence for heighten risk of relapse for laryngeal 
cancer associated with GST-pi over-expression [52]. Others propose the possibility that up-regulated 
GST-pi, GST-mu, and GST-alpha can be predictors of a second primary tumor in head and neck 
cancers [53]. Additional studies demonstrate over-expression of GST-pi within normal mucosa 
adjacent to tumors, dysplastic mucosal lesions, and head & neck squamous cell carcinoma (HNSCC) 
[54,55]. GST-pi expression increases through a step-wise progression, correlating with up-regulated 
NOS and molecular markers of oxidative injury [54,55]. It has been hypothesized that GST-pi is  Int. J. Mol. Sci. 2010, 11                 
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over-expressed in mucosal cells in response to oxidative injury by toxins such as NO
● and known 
nitrosative carcinogens resulting from smoking cigarettes [54,55].  
Presented herein is a study in which we investigated GST-pi expression in laryngeal tumors   
(Table 1). Patient charts were reviewed for TNM stage and course of treatment. Tissue sections were 
reviewed, and the intensity of tumor staining was graded on an immunohistochemical scale (0-4). 
Table 1. GST-pi immunohistochemical staining in human laryngeal tumors. 
Patient Age/Sex 
Tumor 
Location 
Tumor 
Stage 
Surgery Performed 
Previous 
Treatment 
GST-pi 
Intensity 
GST-pi 
Pattern 
1 74/M  Larynx 
T3N0M0 
(recurrent) 
Total laryngectomy  Chemo/XRT  3+  diffuse 
2 79/F 
Pyriform 
sinus 
T3N0M0 Laryngopharyngectomy  None  1+  focal 
3 73/M  Subglottis  T2N0M0  Total  laryngectomy XRT  3+  diffuse 
4 75/F Glottis  T4N0M0  Laryngopharyngectomy None  1+  diffuse 
5 73/M  Supraglottis 
T2N0M0 
(recurrent) 
Supraglottic 
laryngectomy 
XRT 4+  diffuse 
6 63/M  Supraglottis 
T4N2M0 
(recurrent) 
Completion 
laryngectomy 
Supraglottic 
laryngectomy, 
Chemo/XRT 
2+ diffuse 
7 61/M  Supraglottis 
T2N2M0 
(recurrent) 
Completion 
laryngectomy 
Supraglottic 
laryngectomy, 
Chemo/XRT 
4+ diffuse 
8 51/M  Supraglottis 
T4N0M0 
(recurrent) 
Laryngopharyngectomy Chemo/XRT  3+  focal 
9 77/M  Larynx  Recurrent  Total  laryngectomy  Chemo/XRT  3+  diffuse 
10 81/M Larynx 
T3N0M0 
(recurrent) 
Completion 
laryngectomy 
Supraglottic 
laryngectomy 
2+ focal 
Chemo: chemotherapy, XRT: radiation therapy. Study was carried out with IRB approval. 
 
In ten patients, seven had previously undergone radiation therapy; five of the seven patients were 
concurrently treated with chemotherapy and radiation therapy. All patients failed treatment or had 
recurrence or persistent disease. The seven patients who received radiation exhibited higher levels of 
GST-pi expression than the three patients who were not treated with radiation. Figure 1 shows 
examples of GST-pi immunostaining observed in human this study.  
To investigate the commonality among squamous cell carcinomas arising in different sites, we also 
investigated the NOS and GST-pi expression of cervical squamous cell carcinomas (CSCC). Presented 
herein are results showing expression of eNOS, iNOS, and GST-pi in a series of patients with CSCC. 
Patient charts were reviewed for TNM stage, tumor grade, and course of treatment. All samples were 
obtained prior to treatment. Tissue sections were reviewed; the intensity of tumor staining was graded 
on an immunohistochemical scale (0-3). Table 2 summarizes the results.  
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Figure 1. GST-pi immunostaining in human laryngeal tumors. (A) Patient 10, who had 
failed prior surgical treatment without radiation therapy; (B) Patient 5, who had failed prior 
treatment with radiation therapy; (C) Patient 7, who had failed previous treatment with 
radiation therapy. Positive immunohistochemical staining is brown. Images collected at 
100 magnification. 
 
 
Table 2. Cervical cancer patient summary and immunohistochemistry data. 
Patient Age Stage Grade Treatment 
Recurrence/
Persistence 
DFS 
(mos.) 
iNOS 
Intensity 
eNOS 
Intensity 
GST-pi 
Intensity 
1 39  IIB 2  C-R  N  32.5 3+  0  1+ 
2 48  IV 2  N/A  N/A  N/A 2+  0  1+ 
3 65  IIIB  3  C-R  Y  12.5 3+  0  0 
4 41  IIIB  2  C-R  Y  4  2+  0  1+ 
5 39  IIIB  3  C-R  N/A  N/A 2+  1+  2+ 
6 50  IB2 3  C-R  N  37  3+  2+  2+ 
7 38  IB1 2  S  N  39  3+  1+  1+ 
8 49  IB2 2  C-R  N  38  3+  1+  2+ 
9 63  IIIB  2  C-R  Y  9  1+  0  1+ 
10 29  IIB 2  R  N/A  N/A  2+  0  1+ 
11 49  IIIB 2  C-R  Y  8  2+  2+  1+ 
12 49  IIB 3  C-R  N/A  N/A  2+  0  2+ 
13 61  IIIB 3  C-R  N/A  N/A  2+  1+  2+ 
14 63  IIB 2  C-R  N  40  3+  2+  2+ 
15 44  IIB 2  C-R  N  42  3+  1+  2+ 
16 44  N/A 2  N/A  N/A  N/A  2+  1+  1+ 
17 52  IVA 3  N/A  N/A  N/A  3+  1+  2+ 
18 39  IIB 2  C-R  N  39  2+  1+  2+ 
19 51  IIIB 2  C-R  N/A  N/A  2+  1+  1+ 
20 37  IB1 2  S-R  N  35  2+  0  1+ 
21 54  IB2 3  C-R  N  50  2+  1+  1+ 
22 49  IIA 3  R  N  49  2+  1+  1+ 
23 48  IIB 2  C-R  N  48  2+  0  2+ 
Staging by AJCC 2002 criteria. Treatment methods, C: chemotherapy, R: radiation therapy, S: surgery.   
DFS: Disease free survival. iNOS: inducible nitric oxide synthase; eNOS: endothelial constitutive nitric oxide 
synthase; GST-pi: glutathione S-transferase pi. Study was carried out with IRB approval. Int. J. Mol. Sci. 2010, 11                 
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Both iNOS and GST-pi were highly expressed in CSCC, whereas eNOS showed only limited 
expression. Examples of the observed staining are shown in Figure 2. The eNOS expression in CSCC 
was in contrast to previously reported HNSCC work which showed highly expressed eNOS [56,57]. 
Figure 2. Immunohistochemical staining for (A) no primary antibody control; (B) eNOS, 
(C) iNOS, and (D) GST-pi in a single cervical sample. Positive immunohistochemical 
staining is brown. Strong staining is observed for iNOS and GST-pi, while little eNOS 
staining is apparent. Images collected at 250x magnification. 
A B
CD
A B
CD
 
 
Another reported study confirms our findings that NO
● is a significant contributor to cervical 
cancer, and suggests a link between NO
● and a number of prominent risk factors associated with the 
onset of cervical cancer. These factors include: 1) chronic inflammation, 2) HPV infections, 3) 
extended use of oral contraceptives, 4) sexually transmitted diseases, and 5) smoking tobacco [58]. All 
of these factors cause increases in NO
● levels [58-61] and markers of NO
●-mediated mutagenesis in 
patients with cervical intraepithelial neoplasia [58,62,63].  
3. Reactive Nitrogen Species 
The role of reactive nitrogen species (RNSs) has been well documented for many decades. The 
impact of RNSs originates in inflammatory tissues and can result in mutations in tumor suppressor 
genes, leading to subsequent tumor neoplastic growth [64]. RNSs also cause post-translational 
modifications of proteins involved in fundamental cellular functions such as apoptosis, cell cycle 
check point, and DNA repair [65]. RNSs are known to cause both oxidation and nitration reactions 
resulting in DNA strand breaks, mutations in DNA base pairs, and helix modifications [65]. What has 
also become increasingly evident over time is how important the molecular composition of the 
microenvironment is relative to the degree of DNA alterations. The molecular composition of the 
microenvironment is influenced by a number of RNS factors, including: 1) biomolecular profile, 2) 
type, 3) concentration level, 4) accessibility, 5) bioavailability, and 6) half life [65]. RNSs can evolve 
further into a variety of related molecules including 4-hydroxynoneal (4-HNE) and reactive aldehydes-
malondialdehydes (MDA), both of which are associated with increased cancer risk in chronic Int. J. Mol. Sci. 2010, 11                 
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inflammatory diseases [65-67]. Both 4-HNE and MDA are also known to cause point mutations within 
tumor suppressor genes [65-67]. Further, RNSs play a critical role as a facilitator between signal 
transduction receptors such as the MAPK signaling cascade. This can lead to the expression of proto-
oncogenes such as c-Jun, c-Fos, and AP-1. These proto-oncogenes impact differentiation, proliferation, 
cellular death, and transformation [65,68,69]. Free radical exposure is also well recognized to cause 
post-translational modifications which affect the functionality of key cellular proteins. For example, 
exposure to NO
●, an abundant RNS, leads to post-translational modifications of both p53 and Rb 
tumor suppressor genes at critical concentration levels [65,70,71]. Exposure to NO
● also activates 
DNA repair and signal transduction species including DNA protein kinases [65,72,73].  
4. Epigenetics and NO
● 
In the early 1940’s C.H. Waddington first used “epigenetics” to describe the mechanisms 
responsible for the developmental pathway from fertilized egg to an adult [74-76]. Epigenetics is 
known to regulate primary biological functions, including, but not limited to: 1) memory function, 2) 
development and aging, 3) mobile elements activity, 4) genomic imprinting, 5) viral infections, 6) 
somatic gene therapy, 7) cloning, 8) X-inactivation, and 9) the biology of cancer [77-81]. The list of 
diseases associated with epigenetic dysregulation continues to grow as research efforts progress [77-
81]. Over time and with the expanded knowledge base created by the efforts of many, the term has 
evolved to reference the heritable modifications to chromatin, which regulate gene expression, but do 
not change the underlying DNA sequence [75,78,82]. The impact on chromatin composition can be 
rapid and reversible, originating from endogenous and exogenous sources and which may well 
modulate gene expression behavior [47,74,75,82].  
Gene expression and silencing can be carried out via a number of interrelated epigenetic 
mechanisms that may be modulated by NO
●. These mechanisms include, but are not limited to: 1) 
DNA methylation [75,82-84], 2) microRNA (miRNA) [82,85,86], and 3) histone modifications 
[75,78,82,83,85,87-89]. The three mechanisms combine synergistically to regulate and affect 
epigenetic programming and reprogramming behavior [82,85,90-97]. Herein we discuss these three 
mechanisms and the emerging research to date as to how these may be affected by NO
●. Interestingly, 
a recent study involving Duchenne muscular dystrophy indicated that a diminution of NO
● results in 
global epigenetic changes, thereby implicating NO
● as an “epigenetic molecule” [5]. 
4.1. DNA Methylation 
Chromatin is made up of nucleosomes. The nucleosomes are comprised of DNA (146-147 base 
pairs in length, depending upon the literature cited [82,84]) and histones. The DNA is wrapped in a 
left-handed super-helix 1.7 times surrounding a core complex of eight histones [84], two each of H2A, 
H2B, H3, and H4 [82,86]. Each histone within the core has two active functional regions: 1) a 
“histone-fold” area to facilitate histone-to-histone and histone-to-DNA interactions in nucleosomes, 
and 2) a NH2-terminal with COOH-terminal “tails,” which are the sites for post-translational 
modifications that include methylation, phosphorylation, ubiquitination, and acetylation [84]. The tails 
also appear to facilitate linkage between other nucleosomes and/or DNA [87]. Chromatin also allows 
DNA molecules, comprised of millions of nucleotides, hundreds of millions of base pairs in length, to Int. J. Mol. Sci. 2010, 11                 
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be housed highly compressed within the cell nucleus [82,98]. Less tightly bound chromatin usually has 
more reactive sites available for histone alterations, which in turn reversibly modify chromatin 
structure [82]. 
The DNA methylation and chromatin reconfiguration processes have equally prominent, yet 
reversible roles in mediating the genome into transcriptionally expressed or unexpressed segments 
[77,78]. Some patterns of DNA methylation remain constant throughout adulthood, while others are 
reversible. The on-going and mutable role of histones is reversible and also facilitates the silencing or 
unsilencing of gene expression. Tumorigenesis is a key example of pathological dysregulation in 
chromatin remodeling, or a lack of normalcy in DNA methylation processing behavior [77,78]. DNA 
methylation involves the addition of a methyl group at the carbon 5 position of the cytosine ring. The 
event is reversible and is a significant factor in gene expression [77,78]. It takes place primarily within 
the 5’CG3’ (also known as the CpG dinucleotide or CpG loci or sites), which are usually depleted and 
irregularly positioned throughout the genome with weakly concentrated locations. However, more 
dense areas known as CpG islands also exist [89,90,93,99]. CpG sites are usually methylated whereas 
the CpG islands are unmethylated. As we age, this mechanism reverses with intermittent methylation 
of the CpG islands taking place with a corresponding loss of overall methylation patterns throughout 
the genome; this is prominent with oncogenic events [82,90,99]. Abnormal or DNA hypermethylation 
patterns are known to impact promoter regions, which in turn, silence genes and are strongly evident in 
most cancers. Methylation anomalies also fail concurrently to express many tumor suppressor genes, 
further contributing to oncogenesis [82,90,91,99]. The specific relationship among CpG island 
hypermethylation activity, genetic alteration, and epigenetic inactivation of tumor suppressor genes is 
currently being studied in colorectal cancers (CRCs) [100]. CpG islands exist in about 50% of all 
human genes within promoter regions, and when hypermethylated, result in transcriptional silencing 
and tumor suppressor gene activity being down-regulated [100]. A smaller group of CRCs demonstrate 
extensive methylation behavior referred to as CpG island methylator phenotype (CIMP). There are 
three principle mechanisms driving genomic instability in CRCs: 1) CIMP, 2) microsatellite instability 
(MSI), a unique phenotype within CRC, and 3) chromosomal instability (CIN). All three mechanisms 
all contribute to epigenetically alter gene expression in CRCs [101,102]. 
DNA methylation is facilitated by DNA methyltransferases (DNMTs), including DNMT 1, DNMT 
3A, and DNMT 3B [92,99]. Collectively, all three enzymes ensure proper DNA methylation patterns 
[95,99]. DNA methylation (see Table 3 below) is being studied because cancer cells display elevated 
levels of altered DNA methylation patterns when compared to normal cells [77,78]. There are a variety 
of tumor types with associated hypermethylation of at least one gene, including: lung cancer, breast 
cancer, leukemia, and hematologic diseases [77,78,94,96,97]. Certain patterns of hypomethylation can 
also contribute to the formation of other cancer types as well, including but not limited to: metastatic 
hepatocellular cancer, cervical cancer, prostate and B-cell chronic lymphocytic leukemia   
[77,78,103-106]. It has been reported that transcription is impeded when methylcytosine binding 
domain proteins (MBDs) bind to methylated DNA. This binding process interferes with the 
interdependent relationship between the DNA methylation and chromatin reconfiguration processes, 
thereby precluding further gene transcription [78,90].  
 Int. J. Mol. Sci. 2010, 11                 
 
 
2724
Table 3. The epigenetic impact of dysregulated DNA methylation on gene expression and 
human cancers.  
Gene Role/Function  Tumor  Type/Location Impact  Reference(s) 
APC Inhibitor  of  β-catenin 
Aerodigestive tract, lung, 
breast 
Activation β –catenin 
route 
[90,107-109] 
AR Androgen  receptor  Prostate Hormone  insensitivity  [90] 
BRCA1 DNA  repair, 
transcription 
Breast, ovarian  Double strand breaks  [90,110,111] 
CDH1  E cadherin, cell 
adhesion 
Breast, stomach, Leukemia  Dissemination  [90] 
CDH13 H  cadherin,cell 
division 
Breast, lung  Dissemination  [90] 
CDKN2A/
p16 
Cyclin-dependent 
kinase inhibitor 
Head, neck, gastrointestinal 
tract, lung, NHL 
Entrance in cell cycle  [78,90,108,112,113] 
COX2 Cycloxyenase-2  Colon,  stomach Anti-inflammatory 
resistance
1 
[90] 
CPBP1 Retinol-binding 
protein 
Colon, stomach, lymphoma  Vitamin insensitivity  [90] 
DAPK1  Pro-apoptotic  Lymphoma, lung, colon  Resistance to 
apoptosis 
[90,108] 
DKK1 Extracellular  Wnt 
inhibitor 
Colon Activation  Wnt 
signaling 
[90] 
DNMT1 DNA  disruption  Various Over-expression  [90] 
DNMT3b DNA  disruption  Various Over-expression  [90] 
E-cadherin Increasing 
proliferation, 
invasion and/or 
metastasis 
Breast, Thyroid, Gastric    [114-116] 
ER  Oestrogen receptor  Breast, prostate Hormone  insensitivity  [117,118] 
EXT1 Heparan  intermediate 
filament 
Leukemia, skin  Cellular detachment  [90] 
FAT Cadherin,  tumor 
suppressor 
Colon Dissemination  [90] 
GATA4  Transcription factor  Colon, stomach  Silencing of target 
genes 
[90] 
GATA5  Transcription factor  Colon, stomach  Silencing of target 
genes 
[90] 
GSTP1 Conjugation  to 
glutathione 
Prostate, breast, kidney  Adduct accumulation  [90,108,119] 
HIC1  Transcription factor  Various forms  Currently unknown  [90] 
HOXA9  Homeobox protein  Neuroblastoma  Currently unknown  [90] 
hMLH1 Defective  DNA 
mismatch repair, 
gene mutations 
Colon, Renal, Gastric, 
Endometrim, Ovarian 
 [116,120-122] 
ID4  Transcription factor  Leukemia, stomach  Currently unknown  [90] Int. J. Mol. Sci. 2010, 11                 
 
 
2725
Table 3. Cont. 
Gene Role/Function  Tumor  Type/Location Impact  Reference(s) 
IGFBP3 Growth  factor 
binding protein 
Lung, skin  Resistance to 
apoptosis 
[90] 
Lamin 
A/C 
Nuclear intermediate 
filament 
Lymphoma, leukemia  Currently unknown  [90] 
LKB1/ 
STK11 
Serine-theronine 
kinase 
Colon, breast, lung  Currently unknown  [90] 
MBD1 Rare  mutations  Various  Over-expression  [90] 
MBD2 Rare  mutations  Various  Over-expression  [90] 
MBD3 Rare  mutations  Various  Over-expression  [90] 
MBD4 Rare  mutations  Various  Over-expression  [90] 
MeCP2 Rare  mutations  Various  Over-expression  [90] 
MGMT  DNA repair of 06-
alkyl-guanine, p53 
Lung, brain, various  Mutations, 
chemosensitivity 
[90,123,124] 
MLH1 DNA  mismatch 
repair 
Colon, endometrium, stomach, 
ovarian 
Frameshift mutations, 
gene mutations 
[90] 
NORE1A Ras  effector 
homologue 
Lung Currently  unknown  [90] 
p14
ARF  MDM2 inhibitor  Colon, stomach. kidney  Degradation of p53  [90] 
p15    Leukemia, Lymphoma  Entrance in cell cycle  [125-127] 
p15
INK4b Cyclin-dependent 
kinase inhibitor 
Leukemia, lymphoma, lung, 
SCC 
Entrance in cell cycle  [90] 
p16
INK4a Cyclin-dependent 
kinase inhibitor 
Various  Entrance in cell cycle  [90,108] 
p73  P53 homologue  Lymphoma  Currently unknown  [90] 
PR Progestrogen 
receptor 
Breast Hormone  insensitivity  [90] 
PRLR Prolactin  receptor  Breast Hormone  insensitivity  [90] 
RARβ2 Retinoic  acid 
receptor –β2 
Colon, lung, head and neck Vitamin  insensitivity  [90] 
RASSF1A Ras  effector 
homologue 
Lung, breast, ovarian, kidney, 
nasopharyngeal 
Currently unknown  [128-130] 
Rb Cell-cycle  inhibitor  Retinoblastoma, 
oligodenodroglioma 
Entrance to cell  [90,131,132] 
RIZ1 Histone/protein 
methyltransferase 
Breast, liver  Abnormal gene 
expression 
[90] 
SFRP1 Secreted  frizzled-
related protein 1 
Colon Activation  Wnt 
signaling 
[90] 
SLC5A8  Sodium transporter  Glioma, colon  Currently unknown  [90] 
SOC1  Inhibitor of JAK-
STAT pathway 
Liver, mieloma  JAK2 activation  [90] 
SOC3  Inhibitor of JAK-
STAT pathway 
Lung JAK2  activation  [90] Int. J. Mol. Sci. 2010, 11                 
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Table 3. Cont. 
Gene Role/Function  Tumor  Type/Location Impact  Reference(s) 
SRBC BRCA1-binding 
protein 
Breast, lung  Currently unknown  [90] 
SYK  Tyrosine kinase  Breast  Currently unknown  [90] 
THBS1 Thrombospondin-1, 
anti-angiogenic 
Giloma Neo-vascularization  [90] 
TMS1 Pro-apoptotic  Breast  Resistance  to 
apoptosis 
[90] 
TPEF/ 
HPP1 
Transmembrane 
protein 
Colon, bladder  Currently unknown  [90] 
TSHR Thyroid-stimulating 
hormone receptor 
Thyroid Hormone  insensitivity  [90] 
VHL Ubiquitin  ligase 
component 
Kidney, haemangioblastoma  Loss of hypoxic 
response 
[90,129] 
WIF1  Wnt inhibitor factor  Colon, lung  Activation Wnt 
signaling 
[90] 
WRN  DNA repair  Colon, stomach, sarcoma  DNA breakage, 
chemosensitivity 
[90] 
Abbreviations: NHL= Non-Hodgkin’s lymphoma, SCC= Squamous Cell Carcinoma, 
hMLH1= mutant homologue 1. 
 
An additional study demonstrated that NO
● regulates chromatin and gene expression through 
inactivation of nuclear and cytoplasmic proteins by tyrosine-(Tyr) nitration and/or S-
nitrosylation/nitrosation [133]. In S-nitrosylation, primary, tertiary and quaternary protein architecture 
is affected [5]; in Tyr-nitration, the impact is more widespread across a variety of proteins [38]. 
Although NO
● is diffusible, it must also exist physically within the proper microenvironment and 
limited macroenvironment with proteins/substrates in order to react. Evidence of this includes the 
presence of iNOS in the caveolae of endothelial cells, in neurons, and within the nucleus [5,134]. 
Additionally, it has been suggested that NO
●, through S-nitrosylation, impacts a number of targets:  
1) a variety of transcription factors, including tissue specific transcription factors, 2) some 
oncoproteins, 3) DNA binding, and 4) transactivation of nuclear receptors [5]. NO
●-mediated changes 
on transcription factors through Tyr-nitration have also been reported; these changes primarily through 
impacting normal protein-to-protein interactions and limiting nuclear localization [5]. Table 4 lists the 
impact of NO
● on various epigenetic modulators. 
It has further been suggested that DNA is susceptible to transition metal-mediated 
reductive/oxidative modifications which can affect double helix strength [5,135]. Others have 
hypothesized NO
● may be impacting a “genome-wide oscillation” and expression/suppression of 
hundreds of genes, through reactions with thiols/cystine residues in partnership with Fe
2+ ions (both of 
which are believed to reside in chromatin) [5,136,137]. This “genome-wide oscillation” could remain 
in place with oscillating cycles, constructing and deconstructing—of protein complexes, resulting in a 
corresponding impact on transcription processing [5,138]. Finally, there is evidence to suggest 
synthesis of NO
● within the nucleus due to the presence of THB enzymes and two isoforms of NOS 
(eNOS and iNOS) [5,139]. Int. J. Mol. Sci. 2010, 11                 
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Table 4. The epigenetic impact of NO
●. 
Substrate Modification 
Effect on 
Nucleosome/Chromatin 
Transcription
AP-1 S-N  Indirect  - 
AtMYB2 S-N  Indirect  - 
Class II HDACs  Dephosphorylation  Indirect  _ 
c-Myb S-N  Indirect  - 
GR T-N  Indirect  + 
HDAC2 S-N,  T-N  Indirect  + 
HIF-1α S-N  Indirect  + 
Histones T-N  Direct  ? 
ikBα T-N  Indirect  + 
NF-kB S-N,  T-N  Indirect  - 
Notch T-N  Indirect  - 
Nuclear receptors  S-N  Indirect  - 
OxyR and SoxR  S-N  Indirect  + 
P53 T-N  Indirect  - 
PPARγ T-N  Indirect  - 
β –catenin  T-N  Indirect  - 
Abbreviations: S-N= S-Nitrosylation, T-N= Tyr-Nitration. Adapted from reference [5]. 
 
4.2. MicroRNA 
MicroRNAs are relatively small, non-coding RNAs, typically 20-23 nucleotides in size. miRNAs 
originate from 60-110 nucleotide fold-back RNA precursors [90] and have an enormous impact on the 
control of gene expression [99,140,141]. The biosynthetic pathway originates from proteins of the 
Argonaute family. These proteins are transcribed first via RNA polymerase II, and then by RNases III 
Drosha and DGCR8. Finally, in the cytoplasm, RNA III Dicer transforms the proteins into the fully 
functioning miRNA [99,140]. Typically miRNAs act as post-transcriptional regulators by impeding 
protein production of specific messenger RNA (mRNA) molecular species and apparently interacting 
through base-pairing between the 5’-end tails of miRNA (nucleotides 2-8) and the anti-parallel 
sequences of the 3’-untranslated (3’-UTRs) areas within selected mRNAs [141-144]. Originally 
believed to be relatively small in number, there are now over 460 human miRNAs identified [99], with 
the possibility of greater than 1,000 in existence [140]. They have been linked to aberrant cell growth 
patterns and appear to play a dual role in both oncogenesis and tumor suppression, depending upon 
which portion of the genome is being affected. For example, the miR-17-92 cluster has a role in tumor 
neovascularization, when c-myc activates transcription [145,146]. This gene is found to be   
over-expressed in the miR17-92 cluster in B-cell lymphomas and lung cancers. c-Myc also contributes 
to tumor angiogenesis, as well as tumor growth in mouse B-cell lymphoma [145-148]. It has also been 
demonstrated that human cancer types can be classified using expression patterns of miRNA [149]. 
Furthermore, at least one significant relational link has been identified between DNA methylation Int. J. Mol. Sci. 2010, 11                 
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patterns and miRNA; the strength of this relationship is possibly affected by changing the amounts of 
DNMT1, DNMT 3A, and/or DNMT 3B present [98,150,151].  
As is the case with DNA hypermethylation, regulating the abnormal activity levels of certain 
miRNAs could be important in initiating and controlling tumorigenesis. It may be possible to target 
these species through interventions or blocking drugs, such that the miRNAs serve as therapeutic 
molecular markers. Increasing efforts are also being directed towards providing evidence to support 
the development of miRNAs as diagnostic and prognostic products [140]. A few examples include: 1) 
stimulating apoptosis in cultured glioblastoma cells by deprogramming miR-21 (an oncogenic 
miRNA) [152,153], 2) up-regulating miR-372 and 373 in testicular germ cell tumors [99,154], and 3) 
over-expressing miR-155 in both breast cancers and B-cell lymphomas [99,155-157]. Initial clinical 
results using epigenetic drugs, such as 4-phenylbutyric acid (PBA) and 5-Aza-2’-deoxycytidine   
(5-Aza-CdR) exhibit the capability to up-regulate miR-127, which in turn down-regulates Bcl6. This 
finding provides hope that additional therapeutic options will become available by developing drugs 
that act via epigenetic mechanisms [99,158]. It also suggests that epigenetic drugs may be able to  
up-regulate tumor-suppressor genes abnormally de-programmed epigenetically, while also causing 
miRNAs to turn off oncogenic mRNAs [99,159]. 
As research on miRNAs continues to emerge, a number of studies have found a link between NO
● 
expression and a number of different miRNAs. In one study, human umbilical vein endothelial cells 
(HUVECs) were exposed to prolonged unidirectional shear stress, which resulted in the significant  
up-regulation of 13 miRNAs [160]. Among the 13 miRNAs identified, miR-21 exhibited the greatest 
level of up-regulation. miR-21 serves as a regulator of smooth muscle apoptosis [161] and has been 
found to be regulated in both cardiac hypertrophy [162] and human tumors [163]. Notably, HUVECs 
which over-expressed miR-21 exhibited increased eNOS phosphorylation and NO
● production, as well 
as decreased apoptosis. Similarly, another study found that decreasing the levels of miR-145—another 
smooth muscle miRNA regulator—resulted in decreased NO
● expression [164].  
Two other miRNAs have been shown to indirectly modulate iNOS expression: miR-155 and miR-
661. Mice transfected with miR-155 exhibited reduced expression of Suppressor of Cytokine Signal-1, 
and in turn, enhanced iNOS expression [165]. In a different study, human liver cancer cells expressing 
the hepatitis B virus transactivator protein HBx were studied [166]. When the miRNA miR-661 was 
depleted in these HBx-expressing cells, HBx activity was impaired, leading to enhanced iNOS and 
nitrite production.  
4.3. Histone Modifications 
Histones are yet another fundamental epigenetic pathway mechanism and are influential in both 
transcriptional and post-translational modifications [5,82]. These proteins are positively attracted to 
the more negatively charged DNA molecules present, making them particularly susceptible to post-
transcriptional changes in DNA binding through: 1) acetylation, 2) methylation, 3) phosphorylation, 4) 
ubiquitination, 5) SUMOylation (small ubiquinine-like modifier), and 6) isomerization [5,78]. More 
specifically, they also include: 1) lysine acetylation, 2) lysine and arginine methylation, 3) serine and 
threoine phosphorylation, 4) lysine ubiquitylation, and 5) lysine SUMOylation, with over 60 
modification sites currently known [82]. Histone post-translational modifications occur in the globular Int. J. Mol. Sci. 2010, 11                 
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domains and the amino-terminal tails [82,167,168], and along with ATP–dependent chromatin 
remodeling, are among the most significant influencers of gene expression [82]. Coupled with DNA 
methylation activities, these histone mechanisms collectively create an adaptive epigenetic 
environment [82,169]. This is of particular importance towards understanding the enormous impact the 
histone post-translation changes can have on chromatin steric formation. By altering the molecular 
landscape, it transforms transcriptional regulators to interact with cis-DNA binding elements [82]. This 
pattern has been studied and verified in lysine acetylation [82,170].  
Histone modification activities take place primarily through two groups of enzymes. The first, 
histone acetyltranferases (HATs) is comprised of three classes: GNAT, MYST, and CBP/p300. They 
are characterized by the ability to transfer acetyl groups from acetyl-CoA to amino-ε groups for lysines 
within H3 and H4 and are principally responsible for the opening up of chromatin structure, thereby 
permitting access for transcription processes to take place [171]. The second group, histone 
deacetylases (HADCs) reverse the process, resulting in a tightening or constriction of chromatin, 
making the epigenome less accessible to reactions [172]. There are four classes of HDAC enzymes 
[82]. Class I consists of HDAC1, HDAC2, HDAC3, and HDAC8. Class II is further divided into two 
subgroups: IIa, which includes HDAC4, HDAC5, HDAC6, and HDAC7; and IIb, which includes 
HDAC9 and HDAC10. Class III consists of the sirtuins (SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, 
SIRT6, and SIRT7) [173,174]. Class IV is comprised of one enzyme, HDAC11 [172,174]. All play 
significant roles in human physiology and processes, ranging from embryogenesis and cellular 
differentiation to tumorigenesis, by facilitating deacetylating enzymatic reactions [175-177]. 
Significantly, HATs are drawn to promoter locations to become part of protein complexes, and many 
transcriptional co-activators demonstrate HAT enzymatic characteristics [82]. Co-activators have 
emerged as a significant participant in chemical signaling between systemic and cellular metabolism, 
including regulating both mitochondrial oxidative metabolism and the balance between lipid, glucose, 
and energy homeostatic functionality [178]. There are a number of other histone modification 
pathways which we will not explore within the limitations of this review including, but not limited to: 
1) histone methyltransferases, 2) lysine and arginine methyltransferases, and 3) non-SET   
K-methyltransferases. There is synergy and transience between the HATs and HDACs which creates 
an oscillating-feedback loop and reversible gene transcription control mechanism environment.   
Table 5 indicates some of the cancers believed attributable to dysregulated histone protein behavior 
within the epigenome. 
The most recent advances in epigenetic research have been aided by a concurrent evolution of many 
laboratory techniques, including: 1) cDNA microarray, 2) restriction landmark genomic scanning, 3) 
CpG island microarrays, and 4) sodium bisulfate conversion [77,78,179]. Sodium bisulfate is 
particularly useful in differentiating areas of normal and abnormal methylation activity by converting 
unmethylated cytosines to uracil, while leaving methylated cytosines intact. There are a number of 
methods useful in exploring CpG island methylation patterns, including: 1) combined bisulfate 
restriction analyses, 2) methylation-sensitive single nucleotide extension, 3) methylation-sensitive 
single-strand conformational polymorphism, and 4) methylation-specific polymerase chain reaction 
assays [77,78,179,180]. Research efforts have also indicated that preemptive assessment of 
methylation patterns can predict possible malignancies and aid in more timely detection and diagnosis 
of tumors [77,78].  Int. J. Mol. Sci. 2010, 11                 
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Table 5. The epigenetic impact of histone modification on gene expression and human 
cancers. 
Gene Tumor  Type/Location  Impact 
CBP
1  Colon, stomach, endometrium, 
lung, leukemia 
Mutations, translocations, deletions  
EZH2
3  Various types  Gene amplification, over-expression 
GASC1
4  Squamous cell carcinoma  Gene amplification  
HDAC1
2  Various types  Aberrant expression 
HDAC2
2  Various types  Aberrant expression, mutations in MSI+ 
MLL1
3  Haematological malignancies  Translocation  
MLL2
3  Glioma, pancreas  Gene amplification  
MLL3
3 Leukemia  Deletion   
MORF
1 Haematological  malignancies, 
leiomyomata 
Translocations 
MOZ
1 Haematological  malignancies  Translocations 
NSD1
3 Leukemia  Translocation   
p300
1  Colon, stomach, endometrium  Mutations in MSI+ 
pCAF
1 Colon  Rare  mutations 
RIZ1
3  Various types  CpG-island hypermethylation 
Abbreviations: MSI+= Microsatellite instable tumors. Footnotes: 
1 Histone acetyltransferases,   
2 Histone deactylases, 
3 Histone methyltransferases, 
4 Histone demethylase. Adapted from 
references [90,107,109]. 
 
While much progress has already been made, it is clear that the analytical techniques used to study 
epigenetics are still evolving. For example, researchers have attempted to analytically differentiate 
between DNA cytosine methylation (5mC), and hydroxymethylcytosine (hmC). 5mC is involved with 
transcriptional repression, while the functionality of hmC is still unknown. A recent report concludes 
the two compounds are “experimentally indistinguishable” from one another using established 5mC 
mapping criteria and suggest existing 5mC data-bases should be re-examined to ensure that no hmC 
data has been included erroneously [181]. 
To date, only limited data exists regarding the role of NO
● in histone modification. A recent study 
has shown that eNOS gene expression relies upon underlying epigenetic causal mechanisms [82]. It 
was found that when the human eNOS gene in vascular endothelial cells is expressed, the promoter 
region is free of DNA methylation, and histone complexes initiate post-transcriptional changes. H3 
lysine 4 methylation, H3 lysine 9 acetylation, and H4 lysine 12 acetylation all impacted chromatin by 
inducing an open steric formation. These reactions thereby permit access by appropriate transcription 
factors and mechanisms, most important among them, RNA polymerase II at the eNOS promoter 
location [82]. In contrast, the iNOS gene was found to be silent in cultured endothelial cells containing 
hypermethylated CpG dinucleotides within the promoter while they are complexed with the methyl-
binding protein, MeCP2. These reactions result in silencing of post-translational histones H3 lysine 9 
methylation and are suggested to be prevalent in transcriptionally unexpressed heterochromatin. 
Sterically, the chromatin structure is tightly configured, and RNA polymerase II is not present [82]. It Int. J. Mol. Sci. 2010, 11                 
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is also postulated that this and other studies provide evidence that non-expressing cells have the 
necessary transcriptional mechanisms to directly affect eNOS expression, and more significantly, a 
chromatin-linked down-regulating system which prevents eNOS from being expressed in non-
endothelial cells [82,182-184].  
A different study found that the hyporesponsiveness of the iNOS promoter in humans is at least 
partially due to epigenetic silencing in direct response to the hypermethylation of CpG dinucleotides 
and histone H3 lysine 9 methylation [168]. More specifically, the study found that the iNOS promoter 
was highly methylated at CpG dinucleotides in various human endothelial cells and vascular smooth 
muscle cells, two cell types in which iNOS induction is known to be difficult. Furthermore, a human 
pulmonary adenocarcinoma cell line (A549), a colon adenocarcinoma cell line (DLD-1), and primary 
hepatocyte cell cultures are all capable of iNOS induction [168]. The iNOS promoter is 
hypomethylated in DLD-1 cells that have been treated with a DNA methyltransferase. This stimulates 
both global and iNOS promoter DNA hypomethylation. Use of a chromatin immunoprecipitation assay 
showed significant presence of methyl-CpG-binding transcriptional repressor MeCP2 within the iNOS 
promoter location in these endothelial cells. In its entirety the study provided a definition of 
chromatin-based epigenetic mechanisms controlling human iNOS gene expression [168]. 
5. Biological Model System 
As indicated earlier in this review, our prior work has focused on the role of NO
● in both squamous 
cell carcinomas (head & neck, cervix) and adenocarcinomas (lung, breast). We and others have 
reported a spectrum of NOS expression in patient populations of these tumors, as well as other tumor 
types. It has also been observed that patients who present with and/or progress to high levels of NOS 
expression portend to have poorer clinical outcomes than those with low level expression. It has been 
hypothesized that immune system cells are being killed by the comparatively high free radical NO
● 
environment encountered in the tumor bed [185]. Since there is no practical way to study this in human 
patients, we sought to produce a unique, in vitro tissue culture model system of free radical stressed 
tumor cells to determine if in fact they could adapt to increasing levels of NO
●. The resulting model 
system would mimic the spectrum of NO
● expression found clinically [186].  
Our model system was developed by “adapting” low NO
● expressing cell lines to increasing levels 
of NO
● donor. These “parent” cells were gradually exposed to high NO
● (HNO) levels, resulting in a 
new set of HNO cell lines. DETA-NONOate was selected as the NO
● donor for the adaptation process 
due to: a) its high level of free radical donation (two moles of NO
● per mole of DETA-NONOate), and 
relatively long half-life (approximately 24 h. at 37 °C and pH 7.4). During the adaptation process, the 
cell lines successfully withstood incremental increases of 25 µM DETA-NONOate. For each cell line, 
the adaptation endpoint was selected as the concentration in which the exogenous NO
● introduced to 
the cells was lethal to the parent cell lines. At this endpoint concentration, the HNO cells still grow 
robustly and are not morphologically altered from the original (untreated) parent cells. Six different 
parent/HNO cell line pairs have already been developed: one human lung adenocarcinoma cell line 
(A549) [186], one mouse lung adenocarcinoma (LP07) [186], and four human breast adenocarcinomas 
(T-47D, Hs578t, BT-20, and MCF-7) [187]. Ongoing work is focusing on extending this model to 
human head & neck, colon, prostate, and liver tumor cell lines.  Int. J. Mol. Sci. 2010, 11                 
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While the A549 cells were adapted to DETA-NONOate (see Figure 3 below), the A549-HNO cell 
lines were also found to be resistant to other nitrogen-based free radical donors [186,187]. This 
suggests the A549-HNO cell line could have been generated by using any appropriate NO
● donor, and 
that the cells were adapted to the NO
● free radical, and not the donor per se [186,187].  
Figure 3. Adaptation of A549 human lung adenocarcinoma cell line to high nitric oxide 
(HNO) levels. Adapted from reference [186]. 
 
 
Additionally, the lung and breast tumor HNO cell lines were exposed to various concentrations of 
hydrogen peroxide (H2O2), an oxygen-based free radical donor [186,187]. The HNO cell lines were 
more resistant to exposure than the corresponding parent cell lines (see Figure 4 as an example). These 
results show that the HNO cells are similarly resistant to oxygen-based free radicals. 
Figure 4. Treatment of T-47D cell lines (Parent and HNO) to varying concentrations of 
H2O2. Adapted from reference [187]. 
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The reported adaptation process resulted in major biological changes, between the parent and HNO 
cells despite the identical morphology between the two. HNO cancer cell lines exhibited more 
aggressive growth than did their corresponding parent cell lines under both normal and low-nutrient 
growth conditions [186,187].  
The HNO adapted cell lines are comparable to aggressive, fast growing tumors growing in high 
NO
●  environments, while the parent cell lines represent less aggressive, slower growing tumors 
existing in relatively lower NO
● environments. Furthermore, our adaptation process demonstrated that 
long-term NO
● exposure can alter slow growing, less resistant tumors, into faster growing and more 
resistant cancer cells [186,187]. The molecular mechanism for this parent-to-HNO transformation 
remains to be elucidated; however, high concentration levels of NO
● (above 1 µM) are known to 
increase nitrosative cellular stress, which interferes with DNA repair and inhibits zinc finger 
complexes [187-189]. Our model system has proven that tumor cells are able to adapt to comparatively 
high NO
● concentrations, regardless of tumor origin or their histological type. Understanding the role 
of NO
● in tumor cells may in part lie with NO
●-mediated epigenetics.  
As was discussed above, epigenetic alterations that involve aberrant DNA methylation of CpG 
sequences in genes is increasingly being recognized as a key mechanism involved in transcriptional 
silencing of genes in both disease states and, healthy ageing populations [65,82,190]. Our HNO-
adapted cell line system provides a robust, in vitro model for the identification of novel genetic targets 
that are associated with antioxidant stress. We also have evidence that, relative to the MCF-7 breast 
cancer parent cells, the HNO adapted MCF-7 cells demonstrate a significant increase in 
hypermethylation of both HPP1 (70-fold increase) and APC (22-fold increase) tumor suppressor genes 
(see Figure 5 below). 
Figure 5. Methylation of HHP1 and APC in parent and HNO MCF-7 cells. 
 
6. Conclusion 
Research of NO
● has evolved greatly over time. The protective/cytotoxic duality of NO
●, once in 
question, is now generally accepted. As such, current studies are now more intently focused on Int. J. Mol. Sci. 2010, 11                 
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understanding the role of NO
● in cellular toxicity, particularly as it relates to tumor development and 
progression. The association between NOS and GST may be a key component of this story, given that 
over-expression of NOS (regardless of isotype) is often observed in parallel with the over-expression 
of GST (particularly GST-pi). As discussed above, these results are consistent across a number of 
different tumor types, suggesting that NO
● behavior may be more consistent across different tumor 
types than originally thought. Whether this commonality in NO
● behavior exists among different 
tumor types will become more apparent as research is further pursued in the field. The HNO cell line 
model system described above may prove to be a valuable tool for such studies. Similarly, work will 
continue in the area of NO
● and epigenetics. While epigenetic research is still in its infancy, it is 
already clear that NO
● may play an important role in a number of epigenetic functions, including DNA 
methylation, microRNAs, and histone modifications. Thus, while much is already known about the 
biological role of NO
●, even more has yet to be discovered.  
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